U.S. FDA closes Goa plant inspection with one observation
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts more than Nifty Midcap 150 and 0.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The U.S. FDA inspected Lupin's Goa manufacturing facility from October 19 to October 23, 2026, and closed the inspection with one observation. The company plans to address it and respond within the required deadline, and says it aims to meet U.S. manufacturing standards at all facilities.
The single observation adds some regulatory uncertainty, but the filing did not report an import restriction, recall or further U.S. FDA action. The response will be key.